Posters

    Cigarette Smoke Enhances Foam Cell Formation Independent of Scavenger Receptor Gene Expression

    Stolle, K.; Steffen, Y.; Lebrun, S.

    Conference date
    Feb 12, 2010
    Conference name
    Keystone Symposia: Advances in Molecular Mechanisms of Atherosclerosis
    Link to more information
    Topic
    Summary

    Epidemiologic research has shown a correlation between cigarette smoke and the risk of developing atherosclerosis. The unregulated uptake of modified low density lipoprotein (LDL) is a hallmark of atherosclerotic plaque formation, as it leads to foam cell formation, and may be a key step in the progression of cigarette-smoke-related atherosclerosis. In this study, we examined the mechanistic effects occurring in cigarette-smoke-induced foam cell formation in vitro. Macrophages derived from the human acute monocytic leukemia cell line (THP-1) were treated with mainstream smoke total particulate matter (TPM) from the reference cigarette 3R4F (University of Kentucky) for up to 42h. The cells were subsequently treated for 4 hours with fluorescence-labelled acetylated LDL for quantification of foam cell formation or with acetylated LDL for RNA analysis. The uptake of fluorescence-labelled LDL was enhanced dose-dependently in THP-1 macrophages treated with TPM. Gene expression analysis showed that this effect was not correlated with the expression of scavenger receptors. DNA microarray with pathway analysis revealed the involvement of different pathways. This study showed for the first time that foam cell formation of THP-1 macrophages was accelerated by treatment with TPM, independent of differentially expressed scavenger receptors. 

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.